Pfizer Stock Forecast for 2022 - 2025 - 2030
Updated on 12/02/2022
Pfizer Stock Forecast and Price Target
The average target price for Pfizer's stock set by sixteen renowned analysts in recent months is $52.30, representing a potential upside of approximately 2.39% from its last closing price if met by 2023. This estimation is based on a high estimate of $75.00 and a low estimate of $44.00. If you are looking to invest in the stock, it's important to research and compare different companies.
2.39% Upside
Pfizer Fair Value Forecast for 2022 - 2025 - 2030
In the last three years, Pfizer's Price has grown by 47.33%, from $41.58 to $61.26. For the next year, analysts are expecting Fair Value to reach $98.96 – an increase of 61.54%. By 2030, professionals predict that Pfizer's Fair Value will decrease by 26.70%, to $44.91.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
7
|
$161.63 | $164.23 | -1.94% |
| COST Stock Forecast | Costco Wholesale | Outperform |
13
|
$503.86 | $557.59 | 12.13% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
18
|
£112.00 | £136.08 | 28.85% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
14
|
$107.93 | $128.88 | 5.62% |
| BMY Stock Forecast | Bristol-Myers Squibb | Outperform |
2
|
$80.88 | $79.05 | 2.50% |
Pfizer Revenue Forecast for 2022 - 2025 - 2030
In the last three years, Pfizer's Revenue has grown by 99.11%, from $40.83B to $81.29B. For the next year, analysts are expecting Revenue to reach $105.90B – an increase of 30.28%. By 2030, professionals predict that Pfizer's Revenue will decrease by 34.71%, to $53.07B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| AMGN Stock Forecast | Amgen | Hold |
7
|
$285.94 | $246.51 | -9.77% |
| CSL Stock Forecast | CSL | Outperform |
16
|
$298.66 | $228.01 | -28.44% |
| BDX Stock Forecast | Becton, Dickinson and | Outperform |
17
|
$250.83 | $272.08 | 8.04% |
Pfizer Dividend per Share Forecast for 2022 - 2025 - 2030
In the last three years, Pfizer's Dividend per Share has grown from $1.36 to $1.56 – a 14.71% increase. Next year, analysts are expecting Dividend per Share to reach $1.62 – an increase of 3.85%. Over the next nine years, the forecast is for Dividend per Share to grow by 8.33%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| MMM Stock Forecast | 3M | Hold |
16
|
$125.99 | $147.79 | 1.20% |
| 4568 Stock Forecast | Daiichi Sankyo Company | Outperform |
18
|
¥4.60k | ¥0.00 | 13.12% |
| CL Stock Forecast | Colgate-Palmolive | Outperform |
18
|
$77.75 | $80.37 | 4.18% |
Pfizer Free Cash Flow Forecast for 2022 - 2025 - 2030
In the last three years, Pfizer's Free Cash Flow has grown by 115.77%, rising from $13.84B to $29.87B. For next year, analysts predict Free Cash Flow of $34.79B, which would mean an increase of 16.47%. In 2030, professionals predict that Pfizer's Free Cash Flow will decrease by 49.08%, reaching $15.21B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| BAYN Stock Forecast | Bayer | Outperform |
7
|
55.03€ | 67.79€ | 43.56% |
| A Stock Forecast | Agilent Technologies | Outperform |
17
|
$156.12 | $157.63 | 3.77% |
| BAS Stock Forecast | BASF | Outperform |
11
|
47.86€ | 78.27€ | 14.92% |
Pfizer Net Income Forecast for 2022 - 2025 - 2030
In the last three years, Pfizer's Net Income has grown by 97.07%, rising from $11.15B to $21.98B. For next year, analysts predict Net Income of $40.98B, which would mean an increase of 86.43%. According to professionals, by 2030, Pfizer's Net Income will have decreased by 14.38%, falling down to $18.82B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| 4519 Stock Forecast | Chugai Pharmaceutical | Hold |
18
|
¥3.66k | ¥0.00 | 23.09% |
| BIIB Stock Forecast | Biogen | Outperform |
11
|
$301.85 | $242.78 | 7.67% |
| BNTX Stock Forecast | BioNTech | Outperform |
12
|
$169.47 | $0.00 | 20.92% |
Pfizer EBITDA Forecast for 2022 - 2025 - 2030
In the last three years, Pfizer's EBITDA has grown, rising from $13.47B to $31.95B – a growth of 137.24%. In the next year, analysts believe that EBITDA will reach $48.44B – an increase of 51.62%. By 2030, professionals believe that Pfizer's EBITDA will have decreased by 39.14%, falling to $19.44B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ALC Stock Forecast | Alcon | Outperform |
15
|
CHF65.48 | CHF0.00 | 29.15% |
| BN Stock Forecast | Danone | Outperform |
18
|
50.83€ | 62.59€ | 10.17% |
| 4503 Stock Forecast | Astellas Pharma | Outperform |
18
|
¥2.13k | ¥0.00 | 12.83% |
Pfizer EBIT Forecast for 2022 - 2025 - 2030
Pfizer's EBIT has grown In the last three years, rising from $7.36B to $26.85B – a growth of 264.99%. In the next year, analysts believe that EBIT will reach $44.31B – an increase of 65.07%. By 2030, professionals believe that Pfizer's EBIT will decrease by 19.82%, reaching $21.52B – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ALNY Stock Forecast | Alnylam Pharmaceuticals | Outperform |
7
|
$220.25 | $236.31 | 8.06% |
| BAX Stock Forecast | Baxter International | Outperform |
17
|
$52.38 | $65.40 | 22.18% |
| 4523 Stock Forecast | Eisai | Hold |
18
|
¥9.78k | ¥0.00 | -32.48% |
Pfizer EPS Price Prediction Forecast for 2022 - 2025 - 2030
In the last three years, Pfizer's EPS has grown by 47.33%, from $3.00 to $4.42. For the next year, analysts are expecting EPS to reach $7.14 – an increase of 61.54%. By 2030, professionals predict that Pfizer's EPS will decrease by 26.70%, to $3.24.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| CHD Stock Forecast | Church & Dwight | Hold |
11
|
$82.24 | $81.90 | -0.29% |
| ERF Stock Forecast | Eurofins Scientific | Hold |
18
|
68.36€ | 0.00€ | 53.60% |
| BIM Stock Forecast | bioMérieux | Outperform |
18
|
97.48€ | 113.60€ | 6.18% |